Key Facts
- Rating
- Buy (restated by Peel Hunt)
- Price target
- GBX 189
- Potential upside
- 77.63%
- Opening price (Aug 4, 2026)
- GBX 106.40
- Market cap
- £647.12 million
- Insider purchase
- 16,063 shares by John Roche on June 19, 2026
Background
Syncona (LON:SYNC) is a life science investment company focused on creating, building, and scaling companies that deliver transformational treatments in areas of high unmet need. The firm aims to maintain a diversified portfolio of 20-25 globally leading life science businesses across development stage, modality, and therapeutic area.
The company works in partnership with academic founders and experienced management teams to develop treatments that deliver patient impact. As of the latest report, insiders own 0.75% of the company's stock.
Current Situation
On Tuesday, August 4, 2026, Peel Hunt research analysts restated their 'buy' rating on Syncona's stock, according to Digital Look. The firm set a price target of GBX 189, suggesting a potential upside of 77.63% from the company's previous close.
Syncona's shares opened at GBX 106.40 on Tuesday. The stock has a 12-month low of GBX 86.80 and a 12-month high of GBX 109.80. Its 50-day moving average is GBX 103.03, and its 200-day moving average is GBX 97.38. The market capitalization stands at £647.12 million, with a PE ratio of -73.38 and a beta of 0.52.
In insider activity, John Roche purchased 16,063 shares on June 19, 2026, at an average price of GBX 100 per share, totaling £16,063.
| Metric | Value |
|---|---|
| 12-month low | GBX 86.80 |
| 12-month high | GBX 109.80 |
| 50-day moving average | GBX 103.03 |
| 200-day moving average | GBX 97.38 |
| PE ratio | -73.38 |
| Beta | 0.52 |
| Insider ownership | 0.75% |
Impacts
The buy rating and price target from Peel Hunt may influence investor sentiment and trading activity in Syncona's shares. If the market aligns with the target, shareholders could see significant gains, though actual outcomes depend on broader market conditions and company performance.
Insider buying by John Roche could be interpreted as confidence in the company's prospects, potentially affecting other investors' decisions. However, the impact remains uncertain and subject to market dynamics.
Future Outlook
Scenario analysis: The possibilities below are not certain predictions.
If Syncona's stock reaches Peel Hunt's price target of GBX 189, it would represent a substantial increase from current levels. This could occur if the company's portfolio companies achieve clinical or commercial milestones, but such progress is not guaranteed.
Alternatively, if market conditions deteriorate or the company faces setbacks in its investments, the stock may not reach the target. The PE ratio of -73.38 indicates negative earnings, which could pose challenges.
Investors should consider that analyst ratings are opinions and not certainties. The actual future performance of Syncona will depend on various factors, including the success of its life science ventures and overall market sentiment.
Source: tickerreport.com
